Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.

Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ.

Breast Cancer Res Treat. 2015 Apr;150(3):605-11. doi: 10.1007/s10549-015-3355-x. Epub 2015 Apr 2.

PMID:
25833209
2.

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis.

Rose AA, Elser C, Ennis M, Goodwin PJ.

Breast Cancer Res Treat. 2013 Oct;141(3):331-9. doi: 10.1007/s10549-013-2713-9. Epub 2013 Oct 9. Review.

PMID:
24104883
3.

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer.

Cescon DW, Ganz PA, Beddows S, Ennis M, Mills BK, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jul;134(2):759-67. doi: 10.1007/s10549-012-2120-7. Epub 2012 Jun 16.

PMID:
22706631
4.

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1.

Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jun;133(3):1077-88. doi: 10.1007/s10549-012-2012-x. Epub 2012 Mar 14. Erratum in: Breast Cancer Res Treat. 2012 Oct;135(3):923.

5.

Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.

Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N.

J Clin Oncol. 2009 Aug 10;27(23):3757-63. doi: 10.1200/JCO.2008.20.0725. Epub 2009 May 18.

PMID:
19451439

Supplemental Content

Loading ...
Support Center